Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset

Journal of Clinical Investigation

Volumn 101, Issue 9, 1998, Pages 1951-1959

  Nakamura, Norihiko ^a   Ban, Tadanobu ^c   Yamaji, Kenji ^b   Yoneda, Yoshihiro ^c   Wada, Yoshinao ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Annexin V; Apoptosis; Endothelial cell; Inhibition; Lupus anticoagulant

Indexed keywords

LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIGEN BINDING; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; FEMALE; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

EID: 0032080664     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119889     Document Type: Article

References (73)

1. Harris, E.N., A.E. Gharavi, and G.R.V. Hughes. 1985. Anti-phospholipid antibodies. Clin. Rheum. Dis. 11:591-609.
2. Petri, M., M. Rheinshmidt, Q. Whiting-O'Keefe, D. Hellman, and L. Corash. 1987. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann. Intern. Med. 106:524-531.
3. McNeil, H.P., C.N. Chesterman, and S.A. Krilis. 1991. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 49:193-280.
4. Harris, E.N., J.K.H. Chan, R.A. Asherson, V.R. Aber, A.E. Gharavi, and G.R.V. Hughes. 1986. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch. Intern. Med. 146: 2153-2156.
5. Branch, D.W., J.R. Scott, N.K. Kochenour, and E. Hershgold. 1985. Obstetric complications associated with the lupus anticoagulant. N. Engl. J. Med. 313:1322-1326.
6. Feinstein, D.I. 1985. Lupus anticoagulant, thrombosis, and fetal loss. N. Engl. J. Med. 313:1348-1350.
7. Sammaritano, L.R., A.E. Gharavi, and M.D. Lockshin. 1990. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin. Arthritis Rheum. 20:81-96.
8. Bevers, E.M., M. Galli, T. Barbui, P. Comfurius, and R.F.A. Zwaal. 1991. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothronihin. Thromb. Haemost. 66:629-632.
9. Triplett, D.A. 1992. Antiphospholipid antibodies: proposed mechanisms of action. Am. J. Reprod. Immunol. 28:211-215.
10. Vermylen, J., and J. Arnout. 1992. Is the antiphospholipid syndrome-caused by antibodies directed against physiologically relevant phospholipidprotein complexes? J. Lab. Clin. Med. 120:10-12.
11. Santoro, S.A. 1994. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms. Blood. 83:2389-2391.
12. Roubey, R.A.S. 1994. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 84:2854-2867.
13. Rao, L.V.M., A.D. Hoang, and S.I. Rapaport. 1995. Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb. Haemost. 73:668-674.
14. Triplett, D.A. 1995. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb. Res. 78:1-31.
15. Nilsson, T.K., and E. Löfvenberg. 1989. Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant. Clin. Rheumatol. 8:58-63.
16. Tsakiris, D.A., G.A. Marbet, P.E. Makris, L. Settas, and F. Duckert. 1989. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb. Haemost. 61:175-177.
17. Sanfelippo, M.J., and C.J. Drayna. 1982. Prekallikrein inhibition associated with the lupus anticoagulant. Am. J. Clin. Pathol. 77:275-279.
18. Carreras, L.O., and J.G. Vermylen. 1982. "Lupus" anticoagulant and thrombosis-possible role of inhibition of prostacyclin formation. Thromb. Haemost. 48:38-40.
19. Schorer, A.E., N.W.R. Wickham, and K.V. Watson. 1989. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br. J. Haematol. 71:399-407.
20. Martinuzzo, M.E., J. Maclouf, L.O. Carreras, and S. Lévy-Toledano. 1993. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb. Haemost. 70:667-671.
21. Freyssinet, J.-M., M.-L. Wiesel, J. Gauchy, B. Boneu, and J.-P. Cazenave. 1986. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity - a mechanism for thrombosis. Thromb. Haemost. 55:309-313.
22. Tsakiris, D.A., L. Settas, P.E. Makris, and G.A. Marbet. 1990. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J. Rheumatol. 17:785-789.
23. Amer, L., W. Kisiel, R.P. Searles, and R.C. Williams, Jr. 1990. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies, and thrombosis. Thromb. Res. 57: 247-258.
24. Malia, R.G., S. Kitchen, M. Greaves, and F.E. Preston. 1990. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br. J. Haematol. 76:101-107.
25. Smirnov, M.D., D.A. Triplett, P.C. Comp, N.L. Esmon, and C.T. Esmon. 1995. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J. Clin. Invest. 95:309-316.
26. Bokarewa, M.I., K. Bremme, G. Falk, M. Sten-Linder, N. Egberg, and M. Blombäck. 1995. Studies on phospholipid antibodies, APC-resistance, and associated mutation in the coagulation factor V gene. Thromb. Res. 78:193-200.
27. Cariou, R., G. Tobelem, S. Belluci, C. Belluci, J. Soria, C. Soria, J. Maclouf, and J. Caen. 1988. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb. Haemost. 60:54-58.
28. Cervera, R., M.A. Khamashta, J. Font, G. Ramirez, D. D'Cruz, J. Montalbán, A. López-Soto, R.A. Asherson, M. Ingelmo, and R.V. Hughes. 1991. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity. 11:1-6.
29. Gleicher, N., L. Harlow, and M. Zilberstein. 1992. Regulatory effect of antiphospholipid antibodies on signal transduction: a possible model for autoantibody-induced reproductive failure. Am. J. Obstet. Gynecol. 167:637-642.
30. Carreras, L.O., and J. Maclouf. 1993. The lupus anticoagulant and eicosanoids. Prostaglandins Leukot. Essent. Fatty Acids. 49:483-488.
31. Branch, D.W., and G.M. Rodgers. 1993. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am. J. Obstet. Gynecol. 168:206-210.
32. Lockshin, M.D. 1995. Answers to the antiphosphohpid-antibody syndrome? N. Engl. J. Med. 332:1025-1027.
33. Nakamura, N., Y. Shidara, N. Kawaguchi, C. Azuma, N. Mitsuda, S. Onishi, K. Yamaji, and Y. Wada. 1994. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem. Biophys. Res. Commun. 205:1488-1493.
34. Reutelingsperger, C.P.M., G. Hornstra, and H. Hemker. 1985. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur. J. Biochem. 151:625-629.
35. Funakoshi, T., R.L. Heimark, L.E. Hendrickson, B.A. McMullen, and K. Fujikawa. 1987. Human placental anticoagulant protein: isolation and characterization. Biochemistry. 26:5572-5578.
36. Iwasaki, A., M. Suda, H. Nakao, T. Nagoya, Y. Saino, K. Arai, T. Mizoguchi, F. Sato, H. Yoshizaki, M. Hirata, T. Miyata, et al. 1987. Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: a new lipocortin-like protein. J. Biochem. (Tokyo). 102:1261-1273.
37. Tait, J.F., D. Gibson, and K. Fujikawa. 1989. Phospholipid binding properties of human placental anticoagulant protein-I. a member of the lipocortin family. J. Biol. Chem. 264:7944-7949.
38. Creutz, C.E. 1992. The annexins and exocytosis. Science. 258:924-931.
39. Raynal, P., and H.B. Pollard. 1994. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins. Biochim. Biophys. Acta. 1197:63-93.
40. van Heerde, W.L., P.G. de Groot, and C.P.M. Reutelingsperger. 1995. The complexity of the phospholipid binding protein annexin V. Thromb. Haemost. 73:172-179.
41. Nakamura, N., C. Kuragaki, Y. Shidara, K. Yamaji, and Y. Wada. 1995. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am. J. Hematol. 49:347-348.
42. Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, J.C. Schaller, N. Talal, and P.J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheum. 25:1271-1277.
43. Maki, M., M. Murata, and Y. Shidara. 1984. Inhibitors of platelet aggregation and blood coagulation isolated from the human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol. 17:149-154.
44. Wurm, H. 1984. Beta 2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J. Biochem. 16:511-515.
45. Ito, M., M. Watanabe, T. Ihara, H. Kamiya, and M. Sakurai. 1995. Fas antigen and bcl-2 expression on lymphocytes cultured with cytomegalovirus and varicella-zoster virus antigen. Cell. Immunol. 160:173-177.
46. 2-GPI structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179:457-462.
47. 2-glycoprotein-I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 39:1466-1474.
48. 2-glycoprotein-I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154: 954-960.
49. 2 glycoprotein-I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb. Haemost. 75: 717-720.
50. 2-glycoprotein-I and a conventional anticardiolipin immunoassay. Arthritis Rheum. 39:1606-1607.
51. Nakamura, N., C. Azuma, T. Akamizu, H. Sugawa, F. Matsuda, N. Mitsuda, T. Honjo, T. Mori, and K. Yamaji. 1994. Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochem. Biophys. Res. Commun. 203:1789-1794.
52. 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. J. Lab. Clin. Med. 128: 194-201.
53. Roubey, R.A.S. 1996. Immunology of the antiphospholipid antibody syndrome. Arthritis. Rheum. 39:1444-1454.
54. Galli, M. 1996. Non beta 2-glycoprotein-I cofactors for antiphospholipid antibodies. Lupus. 5:388-392.
55. Bennett, M.R., D.F. Gibson, S.M. Schwartz, and J.F. Tait. 1995. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phoshatidylserine. Circ. Res. 77:1136-1142.
56. Bombeli, T., A. Karsan, J.F. Tait, and J.M. Harlan. 1997. Apoptotic vascular endothelial cells become procoagulant. Blood. 89:2429-2442.
57. Casciola-Rosen, L., A. Rosen, M. Petri, and M. Schlissel. 1996. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 93:1624-1629.
58. Rojas, E., H.B. Pollard, H.T. Haigler, C. Parra, and A.L. Burns. 1990. Calcium-activated endonexin II forms calcium channels across acidic phospholipid bilayer membranes. J. Biol. Chem. 265:21207-21215.
59. + transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Biochem. Biophys. Res. Commun. 237:499-503.
60. Arispe, N., E. Rojas, B.R. Genge, L.N. Wu, and R.E. Wuthier. 1996. Similarity in calcium channel activity of annexin V and matrix vesicles in planar lipid bilayers. Biophys. J. 71:1764-1775.
61. Ahn, N.G., D.C. Teller, M.J. Bienkowski, B.A. McMullen, E.W. Lipkin, and C. de Haën. 1988. Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. J. Biol. Chem. 263: 18657-18663.
62. +-binding site in the mechanism of inhibition. J. Biol. Chem. 272: 10474-10482.
63. 2. FEBS Lett. 402:193-197.
64. Schlaepfer, D.D., J. Jones, and H.T. Haigler. 1992. Inhibition of protein kinase C by annexin V. Biochemistry. 31:1886-1891.
65. Routhhut, B., T. Dubois, D. Feliers, F. Russo-Marie, and J-P. Oudinet. 1995. Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Eur. J. Biochem. 232:865-872.
66. King, K.B., S. Chubinskaya, D.L. Reid, L.H. Madsen, and J. Mollenhauer. 1997. Absence of cell-surface annexin V is accompanied by defective collagen matrix binding in the Swarm rat chondrosarcoma. J. Cell. Biochem. 65: 131-144.
67. Goossens, E.L.J., C.P.M. Reutelingsperger, F.H.M. Jongsma, R. Kraayenhof, and W.T. Hermens. 1995. Annexin V perturbs or stabilises phospholipid membranes in a calcium-dependent manner. FEBS Lett. 359:155-158.
68. van Heerde, W.L., K.S. Sakariassen, H.C. Hemker, J.J. Sixma, C.P.M. Reutelingsperger, and P.G. de Groot. 1994. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler. Thromb. 14:824-830.
69. van Heerde, W.L., S. Poort, C. van't Veer, C.P.M. Reutelingsperger, and P.G. de Groot. 1994. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem. J. 302:305-312.
70. Thiagarajan, P., and C.R. Benedict. 1997. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation. 96:2339-2347.
71. Simantov, R., J.M. LaSala, S.K. Lo, A.E. Gharavi, L.R. Sammaritano, J.E. Salmon, and R.L. Silverstein. 1995. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 96:2211-2219.
72. Rand, J.H., X.X. Wu, H.A.M. Andree, C.J. Lockwood, S. Guller, J. Scher, and P.C. Harpel. 1997. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N. Engl. J. Med. 337:154-160.
73. Reutelingsperger, C.P.M., and W.L. van Heerde. 1997. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell. Mol. Life Sci. 53:527-532.